Latest news and press releases about Genelux Corporation (GNLX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer.
Price
| Price | $2.34 |
| Market Cap | $105M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.99 |
| EV / EBITDA | -3.00 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -195.42% |
| Return on Invested Capital | -192.18% |
| Return on Assets | -128.96% |
| Gross Margin | -1762.50% |
| Operating Margin | -445200.00% |
| Net Margin | -422412.50% |
Related companies: ACIU · ALDX · CADL · CLLS · CTNM · DRTS · LXEO
Explore sector: Healthcare · Biotechnology
More sections of GNLX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks